The US Food and Drug Administration (FDA) has approved Abbott’s new longer-length Esprit BTK system for the treatment of chronic limb-threatening ischaemia (CLTI).
The longer-length (76mm) Esprit is designed to improve procedural efficiency by helping physicians treat lesions using fewer devices and supporting a more streamlined workflow. Abbott notes that the device addresses a real-world clinical need, as most below-the-knee (BTK) lesions in CLTI patients exceed 100mm in length. Existing lengths can require multiple Esprit BTK scaffolds, increasing procedural time and complexity.
Esprit Long Length builds on Abbott’s proven Esprit BTK scaffold design and over-the-wire (OTW) platform, which the company highlights is the only dissolving resorbable scaffold (DRS) on the market with robust long-term clinical evidence. Abbott adds that the device is designed for consistent coverage throughout the target lesion with marker systems to support accurate deployment.
“The FDA approval of the Abbott longer-length Esprit BTK scaffold represents an important advancement for physicians treating patients with chronic limb-threatening ischaemia,” said Ethan Korngold, chief medical officer (CMO) of Abbott’s vascular business. “By enabling treatment of longer lesions with fewer devices, this new option can help simplify procedures, improve workflow efficiency, and support more consistent treatment. Building on the proven performance of our Esprit platform, we remain focused on delivering meaningful innovations that address real-world challenges and help physicians improve patient care.”
